Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 14/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 5/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
| ▸ | BRD2 | P25440 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22605085 | 0.79 | RET (0.52) | CYP1A2ALDH1A1TSHRMAPK1CYP2C9 | |
| SCHEMBL1133457 | 0.68 | CYP2C9 (0.47) | TSHRCYP2C9CYP2C19TDP1TLR8 | |
| SCHEMBL13537095 | 0.67 | BRD4 (0.58) | CYP1A2ALDH1A1TSHRMAPK1CYP2C9 | |
| SCHEMBL12301442 | 0.67 | CYP1A2 (0.51) | CYP1A2ALDH1A1TSHRMAPK1CYP2C9 | |
| SCHEMBL26818393 | 0.67 | CCR1 (0.56) | CYP1A2ALDH1A1TSHRMAPK1CYP2C9 | |
| SCHEMBL20720915 | 0.67 | CYP1A2 (0.62) | CYP1A2ALDH1A1TSHRMAPK1CYP2C9 | |
| SCHEMBL30996528 | 0.66 | CYP2E1 (0.41) | CYP2C9CYP2C19 | |
| SCHEMBL29135872 | 0.66 | CYP1A2 (0.49) | CYP1A2ALDH1A1TSHRMAPK1CYP2C9 | |
| SCHEMBL21184318 | 0.66 | BRD4 (0.47) | CYP1A2ALDH1A1CYP2C9BRD4CYP2C19 | |
| SCHEMBL12301359 | 0.66 | CYP1A2 (0.45) | CYP1A2ALDH1A1TSHRMAPK1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977334-B2 | N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity modulator, insulin resistance | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-12 | — | — | US | disclosed |
| US-20090221589-A1 | Use of aminoalcohol derivatives for the treatment of overactive bladder | TRIESELMANN THOMAS | 2009-09-03 | — | — | US | disclosed |
| US-20080234278-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | TRIESELMANN THOMAS | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234278-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | ADRB1, ADRB3, ADRB2 | CYP1A2 88/4885ALDH1A1 674/4885TSHR 527/4885 |
| US-20090221589-A1 | Use of aminoalcohol derivatives for the treatment of overactive bladder | ADRB2, ADRB1, ADRB3 | CYP1A2 102/4885ALDH1A1 172/4885TSHR 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.